Example ISSs for a variety of study designs are available on the CVB website. These are not meant to reflect the only way that study data can be presented, but they do provide acceptable examples. All presentations of study data must meet the following guidelines:
A. Efficacy Studies
Strive to present raw data in a meaningful, concise manner, but do not combine/collapse data so that information is lost.
Example: In example ISS #1, it would have been inappropriate to reduce the data for each calf to an overall yes/no outcome, as there were two parameters (virus and antibody) being evaluated. Information about individual calves would have been lost if those findings were combined into a single composite outcome.
Summarizations: Limited high-level summaries are permissible, but not required, to accommodate readers who do not wish to examine raw data. The following types of summarizations are allowed in addition to raw data:
Totals are allowed for dichotomous or qualitative data, such as total mortalities or the number of animals meeting the criteria of a multi-factorial case definition. Express totals as the number affected over the total number (e.g., 9 of 25 died). Similarly percentages are also allowed as long as the numbers are included (e.g. 9 of 25 (36%)).
It is permissible to include a “final classification” column at end of raw data to show the disposition for each animal (positive or negative). Example ISS #7 illustrates this type of summarization.
Do not include summarizations, such as averages. Do not include statistical analyses, such as prevented fractions or p-values.
B. Safety Studies
For field safety trials (FST) according to VSM 800.204, a tabular presentation is recommended. The presentation may be in one or more tables to present the data adequately.
Present a table listing the AE by category.
The number of AEs may not match the number of animals experiencing AEs, since an animal may experience more than one AE.
AEs that are clearly considered to have a plausible cause other than vaccination may be included in a separate category. (Example: An animal dies a few days after vaccination due to accidental trauma). The explanation must be in the study report with adequate justification (i.e., definitive data) to rule out vaccination. Such AEs may be indicated as “affirmed by licensee to have a cause other than vaccination.” Example ISS #15 shows this type of summary.
Explanatory notes may be included to indicate circumstances that may affect the interpretation of the observations or where there is not a sufficient degree of certainty to designate the AEs as having a cause other than vaccination. In that case a short, concise explanation may be provided below the table. (Example: Pigs vaccinated with a Mycoplasma hyopneumoniae bacterin are part of a herd that experiences an influenza outbreak a couple of days later.) Example ISS #16 shows this type of summary.
Where appropriate, present a table of injection site swelling. Tabulate local injection site swelling by size and duration. Example ISS #10 shows this type of summary.
For poultry studies, include data for mortality, hatchability, and condemnation. Mortality and condemnation data are required for all poultry studies. Hatchability data are required for products administered in ovo. If the data are not available, make an explanatory notation . Mortality, hatchability, and condemnation data may be presented as percentages as long as total animal numbers are reported. Example ISS #14 shows this type of summary.
C. Exceptions for Historical Studies
The data requirements described in Sections V.A and V.B are expected for all summaries for studies conducted in 2017 forward. It is highly likely that studies of the past several years also will have the detail necessary to meet these requirements. The CVB recognizes that some older study reports may not have the detail necessary to meet all of the summary requirements, and these will be handled on a case-by-case basis to best present the available data.
Questions may be directed to CVB.Single.Tier@aphis.usda.gov.